Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244972 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT00244972: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00244972 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 74 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244972, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of tipifarnib when given together with sorafenib tosylate in treating patients with biopsiable cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Tipifarnib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Tipifarnib
- DRUG Sorafenib Tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2005-10 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244972
The ClinicalTrials.gov registry entry for NCT00244972 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00244972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244972 about?
NCT00244972 is a clinical study titled "Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer". This phase I trial studies the side effects and best dose of tipifarnib when given together with sorafenib tosylate in treating patients with biopsiable cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Tipifarnib and sorafenib tosylate may ...
What is the current status of trial NCT00244972?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2005-10. Estimated completion is 2017-03.
What interventions are being tested in trial NCT00244972?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tipifarnib (DRUG), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT00244972?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.